MAPS platform

MAPS platform: a next generation vaccine technology.

Affinivax’s proprietary Multiple Antigen Presenting System (MAPS) platform employs a novel technology that dramatically simplifies vaccine design while significantly enhancing the depth and breadth of protection against many of the most challenging infections and other diseases. We believe MAPS represents a significant advance in vaccine technologies because of its ability to induce a much broader protective immune response – from both the polysaccharide and protein antigens – that has not been possible with conventional conjugate vaccine technologies.

Patented binding approach streamlines the process of vaccine design. Using a proprietary approach, MAPS allows for multiple polysaccharide and protein antigens to be effectively incorporated in a single vaccine, achieving the potential for unprecedented levels of immune response and disease protection.

How MAPS Technology Works

With its MAPS platform, Affinivax has taken a completely novel approach to vaccine development that streamlines the process of vaccine design. MAPS utilizes a patented high affinity biotin-rhizavidin binding interaction to uniquely present key immunogenic epitopes of both the polysaccharide and protein antigens to induce robust immune protection – including B-cell and T-cell responses – in a single vaccine.

Learn about the advantages of our MAPS vaccines.

Proprietary binding of polysaccharides to proteins

The MAPS technology circumvents the complex and inefficient chemistry of traditional vaccine conjugation; it uses a proprietary binding approach that capitalizes on the highly specific and durable non-covalent, affinity binding between biotin and rhizavidin, a biotin-binding protein. The highly stable construct created by this affinity binding contributes to a simple, modular, and efficient approach to the development and production of MAPS vaccines.

Broad immune protection: Combining polysaccharides and protein antigens

The MAPS vaccine technology platform is designed to provide broader immune protection against a wide range of diseases by combining both protective polysaccharide and protein antigens in a single vaccine to induce effective immune responses to both components. This is in contrast to conventional conjugation approaches that rely on covalent binding between polysaccharides and protein antigens, which may result in polysaccharide epitope damage and do not induce a broad immune response to the protein antigen.

Broad immune protection: Including species-conserved protein antigens

The novel MAPS approach allows for the inclusion of species-conserved protein antigens that not only act as carriers to elicit an immune response against the polysaccharides, but also act as immunogens themselves, thereby broadening the immune response. MAPS vaccines are thus able to induce broad immune responses directed against both B- and T-cell antigens, to induce protection against infectious and immune-mediated diseases.

Ease of design and manufacturing

With a precise, reproducible and modular high-affinity binding of the core vaccine components (the polysaccharides and proteins), the MAPS technology enables a flexible, plug-and-play vaccine design and greater ease of manufacturing, offering the potential for accelerated development to lead candidates and entry into clinical trials.

Unique benefits of MAPS: broad, robust, protective immune response.

Our MAPS platform enables our vaccines to have uniquely broad and protective immune response – including a B-cell immune response to the polysaccharides and B cell and T-cell immune responses to the proteins – without the requirement for a novel adjuvant. The potential for a broader and more robust immune response to both polysaccharide and protein antigens differentiates our MAPS platform from polysaccharide conjugate vaccine technologies, where the protective immune response is primarily based on the polysaccharides. Thus, MAPS extends the functionality of the protein, beyond its role in conventional conjugate vaccines as primarily a carrier of the polysaccharide antigen, to also trigger a B- and T-cell immune response to itself – significantly broadening the protective efficacy against multiple pathogens.

Affinivax has strong intellectual property. The company has an exclusive license from Boston Children’s Hospital to intellectual property on the MAPS technology platform, initially developed in the laboratories of Richard Malley, MD, Affinivax’s scientific founder, Professor of Pediatrics at Harvard Medical School, and the Kenneth McIntosh Chair in Pediatric Infectious Diseases at Boston Children’s Hospital. The licensed intellectual property covers proprietary compositions and methods of use pertaining to the MAPS core technology platform – biotin and rhizavidin binding proteins – as well as several conserved protein antigens. This licensed intellectual property also includes a very broad field of use, enabling the pursuit of preventive, therapeutic and diagnostic applications of the MAPS technology across all therapeutic disease areas. With this strong patent portfolio, Affinivax is advancing a novel product pipeline in infectious and other immune-mediated diseases.

Trade marks are owned by or licensed to the GSK group of companies.
©2022 GSK group of companies or its licensor.

Back to Top

This links to an external website.